Immunotherapy combo for advanced lung cancer or melanoma
Part of Cancer, Lungs & breathing, Skin clinical trials.
This trial tests a combination of immunotherapy drugs (anti-PD-1/PD-L1 antibodies) plus bevacizumab and a low-dose chemotherapy called cyclophosphamide for people with advanced lung cancer or melanoma who have already been on immunotherapy and their cancer has progressed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have been diagnosed with advanced non-small cell lung cancer (without certain gene mutations) or melanoma that has spread, and you have already received immunotherapy (like a PD-1 or PD-L1 blocker) for more than 6 months and your cancer got worse
- If you have melanoma with a BRAF V600 mutation, you must have also tried BRAF/MEK inhibitor therapy
- You are generally well enough to be up and about (ECOG performance status 0-2)
- You do not have serious heart problems, uncontrolled high blood pressure, or a history of blood clots
- Your blood counts and liver/kidney function are within acceptable ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (iSCIB1+) combined with two standard immunotherapy drugs (ipilimumab and nivolumab) as the first treatment for advanced melanoma that cannot be removed by surgery. The goal is to see if adding iSCIB1+ helps the immune system fight the cancer better.
This trial tests a combination of immunotherapy drugs (checkpoint inhibitors) delivered directly into the liver along with standard treatment, as a first option for people with inoperable lung cancer. It aims to see if this approach can help shrink tumors and improve outcomes.
This trial tests a three-drug combination (ipilimumab, nivolumab, and nogapendekin alfa inbakicept) as a first treatment for people with stage IV or recurrent non-small cell lung cancer. The goal is to see if this approach can help your immune system fight the cancer more effectively.
This trial tests a new combination of two immunotherapy drugs plus a targeted therapy (bevacizumab) for people with advanced melanoma whose cancer continued to grow after previous immunotherapy. The goal is to see if this combination can help control the cancer.
This trial tests a combination of two drugs (cadonilimab and interferon) given before surgery to treat advanced melanoma that has spread to nearby lymph nodes or one distant site. The goal is to shrink tumors and improve chances of successful surgery and long-term survival.
This trial tests a combination of two immunotherapy drugs with standard chemotherapy (bevacizumab, albumin-bound paclitaxel, and carboplatin) for people with advanced acral or mucosal melanoma. The goal is to see if this combination can shrink tumors or slow the cancer's growth better than current treatments.
Hear when a new Metastatic Cutaneous Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.